Form 4: Grace Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Brian Davis, a director at Grace Therapeutics, acquired stock options for 10,000 shares at an exercise price of $2.72 on May 9, 2025.
Summary
- On May 9, 2025, Brian Davis, a director of Grace Therapeutics, Inc., acquired stock options for 10,000 shares.
- The exercise price of these options is $2.72 per share.
- 50% of the options vest immediately, with the remaining 50% vesting in equal monthly installments until September 30, 2025, contingent upon continuous service.
- Following the transaction, Davis directly owns options for 10,000 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It reports a transaction without expressing any positive or negative outlook.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 2025/04/08 | Date of Power of Attorney execution. |
| 2025/05/09 | Date of the stock option grant. |
| 2025/05/09 | 50% of the options vest on this date. |
| 2025/05/13 | Date of Form 4 filing. |
| 2025/09/30 | Remaining 50% of options vest in monthly installments until this date. |
| 2035/05/09 | Expiration date of the stock options. |
Keywords
stock options, Form 4, Grace Therapeutics, director, Brian Davis, beneficial ownership, securities, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.